Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease

Study answer

What this study found

Phylloquinone clearly improved vitamin K status, but it did not translate into meaningful bone health benefits over 12 months. In Study A, %ucOC fell from 47% at baseline to 28.1% with 1000 mg/day and 28.95% with 2000 mg/day, with both doses better than baseline (P<0.01) and no difference between doses. Serum phylloquinone increased dose-responsively from 0.64 (0.50-1.54) nmol/l pre-intervention to 3.42 (2.58-9.24) nmol/l with 1000 mg/day and 16.4 (8.55-25.5) nmol/l with 2000 mg/day, versus 0.63 (0.54-1.05) nmol/l with placebo (P<0.0001). Over 12 months, there were no significant changes in…

Study & population

Interventional human study in adults with Crohn's disease in clinical remission recruited from an IBD clinic in Cork, Ireland.

Intervention

This paper evaluated oral phylloquinone (vitamin K1) supplementation in adults with Crohn's disease in remission.

Key limitation

Small active-arm sample sizes, especially in the 2-week dose-ranging phase, limit precision.

View full study detailsView sourceOpen PDF

Original abstract